Collaboration accelerates patient enrollment in genetic Parkinson’s study

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/digicomphoto)
(Image: Getty/digicomphoto)

Related tags: Parkinson's disease, Recruitment, Clinical trial, Clinical trial participants, Genetics, Rare disease, Neurology

Centogene and Denali entered a strategic collaboration to identify and recruit patients with a gene mutation to be enrolled in a Parkinson’s disease study.

Centogene will use its dried blood spot collection kit, CentoCard, to help identify Parkinson’s disease (PD) patients with a mutation on the LRRK2 gene​ that can be enrolled in Denali’s clinical study for the treatment of Parkinson’s.

Arndt Rolfs, CEO and founder of Centogene, told us the company works worldwide identifying rare hereditary diseases​, but is especially active in regions where intra-familial marriage is prevalent. According to Rolfs, rare hereditary diseases are more frequently seen in those regions.

This process will help recruit for a global study Denali is conducting, focused on the early identification and characterization of LRRK2 in PD patients. It is believed that a mutation in the LRRK2 gene is a driver of lysosomal dysfunction. This type of dysfunction leads to the build-up of Lewy body protein aggregates and neurodegeneration seen in PD.

“What is really important for Denali, is to have untreated patients, and that is a big challenge,”​ said Rolfs. Identifying patients who have PD but also have the genetic mutation will provide for a better understanding of treatment.

Centogene will employ CentoCard as a means of identifying individuals with this genetic mutation. Rolf told us, “It [the CentoCard] is a very simple but extremely effective way as a logistic solution to transport the blot material all over the globe. The CentoCard is a simplified piece of paper. A drop of blood from the patient is sufficient to do the entire genetic and biomarker casting.”

Rolf explained that the card is stable for shipping since “you just put a drop of blood on the surface of the paper, you let it dry and then its stable for years and you can put it in a simple envelope.”​ He told us this will make identifying possible participants more efficient and cost-effective, since no blood work needs to be drawn and shipped worldwide in a vial.

Patients with this type of mutation represent between 1-5% of the PD population. Therefore, screening involves testing a large number of individuals to find one person with an LRRK2 positive mutation. Centogene has developed mathematical modulations that have shown that per the collaboration the, time spent identifying patients will decrease from 3-5 years to 12-18 months.

Related news

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Related suppliers

Follow us

Products

View more

Webinars